Nevirapine plus didanosine: Once or twice daily combination? [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 1, 2000, Pages 93-95

  Van Heeswijk, Rolf P G ^a   Veldkamp, Agnes I ^a   Mulder, Jan W ^b   Meenhorst, Pieter L ^b   Wit, Ferdinand W N M ^c   Reiss, Peter ^c,d   Lange, Joep M A ^c,d   Kwakkelstein, Marthin O ^e   Beijnen, Jos H ^a   Hoetelmans, Richard M W ^a  

^a Department of Pharmacy and Pharmacology ^*  (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c Natl AIDS Therapy Evaluation Centre   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; DIDANOSINE; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; NEVIRAPINE;

AREA UNDER THE CURVE; CASE REPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL;

EID: 0034273759     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200009010-00014     Document Type: Letter

References (11)

1. Didanosine. An update on its activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease
2. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
3. The ATLANTIC study. A randomised open-label study comparing two protease inhibitor (PI) sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data
4. Once-daily therapy (NVP/ddI/3TC) for the IVDU HIV-1-infected population of the Frankfurt HIV-cohort
5. The VIRGO Trial: d4T/ddI(qd)/nevirapine (bid or qd) in antiretroviral-naive HIV-1-infected patients - A convenient and potent regimen
6. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1-infected individuals
7. Comparison of the steady-state pharmacokinetics of nevirapine (Viramune) in a once daily (qd) and twice daily (bid) dosing regimen
8. Nevirapine: A review of its development, pharmacological profile and potential for clinical use
9. No relationship between gastric pH, small bowel bacterial colonisation, and diarrhoea in HIV-1-infected patients
10. Antacids revisited. A review of their clinical pharmacology and recommended therapeutic use
11. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase liquid chromatography with ultraviolet detection